Protein-C at Dr. Essa Lab

Protein-C at Dr. Essa Lab

The Protein-C test is a highly specialized blood investigation designed to measure the activity or concentration of Protein C in the blood. Protein C is a natural, vitamin K-dependent anticoagulant protein synthesized by the liver. It plays a critical role in regulating the body’s coagulation cascade by inactivating specific clotting factors, namely Factor Va and Factor VIIIa, in the presence of its cofactor, Protein S. When Protein C is activated by the thrombin-thrombomodulin complex on the endothelial cell surface, it acts as a physiological brake on thrombin generation, preventing excessive and dangerous blood clot formation within blood vessels. A deficiency or dysfunction in this vital protein can lead to an unchecked hypercoagulable state, also known as thrombophilia, which significantly increases an individual’s risk of developing venous thromboembolism (VTE), deep vein thrombosis (DVT), and life-threatening pulmonary embolism (PE).

At Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, the Protein-C assay is performed using state-of-the-art automated coagulation analyzers. These advanced systems utilize highly precise chromogenic or clot-based functional assays to evaluate how effectively the patient’s Protein C can inhibit clot formation. Measuring functional activity is clinically superior to merely measuring the quantity of the protein, as some patients may have normal levels of a dysfunctional protein (Type II deficiency). This diagnostic evaluation is of paramount clinical importance for patients presenting with unexplained thrombotic episodes, a strong family history of clotting disorders, or recurrent pregnancy losses. By providing precise, reproducible, and timely results, Dr. Essa Lab enables hematologists, cardiologists, and obstetricians to make informed decisions regarding long-term anticoagulation therapy, risk stratification, and preventive healthcare management.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is absolutely critical for the accuracy of a Protein-C test, as several physiological states, medications, and acute illnesses can temporarily alter Protein C levels, leading to diagnostic errors. Patients must strictly adhere to the following preparation guidelines:

• Timing of the Test: The Protein-C test should not be performed during an acute thrombotic event or inflammatory state. Acute clots consume clotting factors and regulatory proteins, which can temporarily lower Protein C levels and produce a false-positive result for congenital deficiency. It is highly recommended to wait at least 4 to 6 weeks after an acute thrombotic episode before undergoing testing.
• Anticoagulant Medication Discontinuation: Oral anticoagulants, particularly vitamin K antagonists like Warfarin, directly suppress the synthesis of functional Protein C. Testing a patient currently taking Warfarin will show a falsely low Protein C level. Patients must discontinue Warfarin for at least 2 weeks prior to the test, strictly under the supervision and approval of their prescribing physician. If anticoagulation cannot be safely stopped, alternative bridging therapies (such as low-molecular-weight heparin) may be managed by the clinician, though heparin itself can sometimes interfere with certain clot-based assays. Direct oral anticoagulants (DOACs) like Rivaroxaban or Apixaban should also be noted, as they can interfere with clot-based functional assays.
• Fasting Requirements: While a strict overnight fast is not universally mandatory for a basic Protein-C test, a light fast of 4 to 12 hours is often recommended to prevent lipemia (excess fat in the blood), which can interfere with the optical detection systems used in automated coagulation analyzers.
• Hydration: Patients should remain well-hydrated by drinking plenty of plain water before the blood draw, as dehydration can affect blood viscosity and sample quality.
• Medical History Disclosure: Patients must inform the laboratory staff and their physician about all current medications, pregnancy status, recent surgeries, or active liver disease, as these factors significantly influence the interpretation of the results.

During the Procedure

The collection of a blood sample for a Protein-C test at Dr. Essa Lab follows strict clinical protocols to ensure sample integrity and patient safety:

• Patient Positioning: The patient is comfortably seated in a specialized blood collection chair. The phlebotomist will ask the patient to extend their arm and rest it on a stable support.
• Vein Selection and Sanitization: The phlebotomist inspects the antecubital fossa (the crease of the elbow) to locate a suitable, prominent vein. Once selected, the area is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) using a circular motion from the center outward, and allowed to air dry completely to prevent hemolysis.
• Tourniquet Application: A tourniquet is applied 3 to 4 inches above the puncture site to increase venous pressure and make the vein more visible and accessible. The tourniquet is left on for less than one minute to avoid hemoconcentration, which can alter coagulation factor concentrations.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection system is gently inserted into the vein. For coagulation studies, blood must be collected in a light blue-top tube containing 3.2% buffered sodium citrate. This specific anticoagulant binds calcium in the blood, preventing clotting during transport and processing while preserving the functional activity of the proteins.
• Order of Draw: If multiple blood tests are being performed, the citrate tube must be drawn before other tubes containing additives (like EDTA or heparin) to prevent cross-contamination of anticoagulants, which would invalidate the coagulation assay.
• Sample Mixing: Immediately after filling the tube to the designated fill line (ensuring the precise 9:1 blood-to-anticoagulant ratio), the phlebotomist gently inverts the tube 3 to 4 times to mix the sodium citrate thoroughly with the blood. Vigorous shaking is strictly avoided to prevent hemolysis and premature activation of platelets.
• Post-Puncture Care: The needle is smoothly withdrawn, and immediate, gentle pressure is applied to the puncture site with a sterile gauze pad to promote hemostasis. A small adhesive bandage is applied once bleeding has stopped. The entire venipuncture process takes less than five minutes and involves minimal discomfort, comparable to a mild pinch.

When is a Protein-C Performed?

Unexplained Venous Thromboembolism (VTE)

Physicians frequently request a Protein-C test when a patient experiences an unexplained or unprovoked blood clot, such as a deep vein thrombosis in the lower extremities or a pulmonary embolism in the lungs, particularly at a young age (under 50 years). In these cases, there are no obvious predisposing factors like major surgery, prolonged immobilization, or active malignancy. Identifying an underlying congenital or acquired Protein C deficiency helps clinicians understand the root cause of the thrombotic event, determine the appropriate duration of anticoagulant therapy, and implement preventive measures to avoid recurrent episodes.

Family History of Inherited Thrombophilia

A family history of early-onset venous thromboembolism or known hereditary clotting factor deficiencies is a strong clinical indication for a Protein-C test. Inherited Protein C deficiency is an autosomal dominant disorder. If a first-degree relative has been diagnosed with congenital Protein C deficiency or has suffered from severe, unexplained blood clots, screening other family members can identify asymptomatic carriers. This allows healthcare providers to counsel these individuals on lifestyle modifications and provide prophylactic anticoagulation during high-risk periods, such as major surgeries, prolonged travel, or pregnancy.

Recurrent Pregnancy Loss (Miscarriages)

Recurrent pregnancy loss, defined as two or more consecutive miscarriages, is a deeply distressing clinical scenario that warrants a comprehensive thrombophilia workup, including a Protein-C test. During pregnancy, the body naturally shifts toward a hypercoagulable state to prevent excessive bleeding during delivery. However, if an underlying maternal Protein C deficiency exists, this hypercoagulability can become exaggerated, leading to microvascular thrombosis within the developing placental circulation. This restricts blood flow, oxygen, and nutrient delivery to the fetus, potentially resulting in early miscarriage, late-term fetal loss, preeclampsia, or intrauterine growth restriction (IUGR).

Neonatal Purpura Fulminans or Severe Deficiency

In rare and severe cases, infants born with homozygous or compound heterozygous congenital Protein C deficiency present shortly after birth with a life-threatening condition known as purpura fulminans. This condition is characterized by widespread microvascular thrombosis, skin necrosis, and disseminated intravascular coagulation (DIC). Pediatricians and neonatologists urgently request a Protein-C test in newborns exhibiting these severe symptoms or those with unexplained, rapidly progressing skin lesions. Rapid diagnosis is critical, as these neonates require immediate, life-saving replacement therapy with Protein C concentrates or fresh frozen plasma.

Evaluation of Warfarin-Induced Skin Necrosis

Warfarin-induced skin necrosis is a rare but severe complication that can occur when a patient with an unrecognized, underlying Protein C deficiency initiates Warfarin therapy without adequate heparin bridging. Because Protein C has a much shorter half-life (about 6 to 8 hours) than other vitamin K-dependent clotting factors (such as Factor II and Factor X), initiating Warfarin causes a rapid, transient drop in Protein C levels before the procoagulant factors decline. This creates a temporary, extreme hypercoagulable state, leading to microvascular thrombosis and localized skin necrosis, typically in areas with high fat content. A Protein-C test helps confirm this underlying risk factor in patients who experience this complication.

What Does a Protein-C Detect?

The Protein-C test is highly sensitive and specific in detecting various quantitative and qualitative abnormalities in the coagulation system. Specifically, this diagnostic assay can detect, evaluate, or assist in the clinical management of:

• Congenital Protein C Deficiency (Type I): Characterized by a parallel decrease in both the functional activity and the physical antigen concentration of Protein C in the blood, representing a quantitative defect.
• Congenital Protein C Deficiency (Type II): Characterized by normal or near-normal antigen levels but significantly reduced functional activity, representing a qualitative defect where the protein is present but does not function correctly.
• Acquired Protein C Deficiency due to Liver Disease: Since Protein C is synthesized in the liver, advanced hepatic disorders such as cirrhosis, hepatitis, or liver failure lead to decreased production and lower blood levels.
• Severe Vitamin K Deficiency: Protein C synthesis requires vitamin K; a severe deficiency of this vitamin impairs the gamma-carboxylation process, resulting in dysfunctional, inactive Protein C molecules.
• Disseminated Intravascular Coagulation (DIC): An acute, life-threatening systemic process where widespread activation of the clotting cascade consumes large quantities of coagulation factors and regulatory proteins, including Protein C.
• Active Deep Vein Thrombosis (DVT): Temporary consumption of Protein C during an active clotting event, which helps clinicians assess the severity and dynamics of the thrombotic process.
• Active Pulmonary Embolism (PE): Consumption-related decreases in Protein C activity during acute pulmonary vascular occlusion.
• Effectiveness of Vitamin K Antagonist Therapy: Monitoring the suppression of vitamin K-dependent proteins, although not the primary tool for monitoring Warfarin, it detects the physiological impact of the drug.
• Risk of Recurrent Venous Thromboembolism: Identifying patients with persistently low Protein C levels who have a significantly higher risk of experiencing recurrent thrombotic events.
• Predisposition to Obstetric Complications: Detecting maternal hypercoagulability that could lead to placental thrombosis, preeclampsia, or fetal growth restriction.
• Asymptomatic Thrombophilia Carrier State: Identifying individuals who carry a genetic mutation for Protein C deficiency but have not yet experienced a clinical thrombotic event.
• Neonatal Homozygous Deficiency: Detecting near-zero levels of Protein C in newborns presenting with neonatal purpura fulminans.
• Septic Shock-Induced Coagulopathy: Severe sepsis can cause endothelial dysfunction and downregulate the thrombomodulin-Protein C pathway, leading to acquired deficiency and microvascular clotting.
• Antiphospholipid Syndrome (APS) Interference: Evaluating clotting abnormalities in patients with APS, where lupus anticoagulants can sometimes interfere with certain clot-based Protein C assays.
• Estrogen-Induced Hypercoagulability: Assessing mild, acquired decreases in Protein C activity associated with high-dose oral contraceptive use or hormone replacement therapy.
• Post-Operative Hypercoagulability: Monitoring transient drops in natural anticoagulants following major orthopedic or cardiothoracic surgeries.
• Renal Disease-Associated Thrombosis: Evaluating altered coagulation profiles in patients with nephrotic syndrome, where proteins can be lost in the urine.
• Inflammatory Bowel Disease (IBD) Coagulopathy: Assessing acquired thrombophilic risks in patients with active Crohn’s disease or ulcerative colitis, which are associated with systemic inflammation and altered protein levels.
• Malignancy-Associated Hypercoagulability: Evaluating the complex interactions between tumor cells and the coagulation system, which can consume natural anticoagulants.
• Efficacy of Protein C Concentrate Replacement: Monitoring therapeutic levels in patients receiving exogenous Protein C concentrates for severe deficiency states.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing rapid, accurate, and highly reliable diagnostic reports. For specialized coagulation assays like the Protein-C test, the turnaround time typically ranges from 24 to 48 hours, as these tests require precise sample preparation, including double centrifugation to obtain platelet-poor plasma, and specialized automated testing protocols. Once the analysis is complete, the results undergo a rigorous multi-level review process by qualified clinical pathologists and hematologists to ensure absolute accuracy and clinical validity.

Patients can access their diagnostic reports conveniently through multiple digital channels. Dr. Essa Lab offers a user-friendly online portal on their official website, where patients can securely log in using their lab ID and password to view, download, or print their reports. Additionally, patients receive real-time SMS notifications containing a direct link to download their digital reports as soon as they are finalized. For added convenience, physical reports can also be collected from any of the numerous Dr. Essa Lab collection centers across Karachi and other major cities, or delivered directly to the patient’s home through their dedicated dispatch service.

Protein-C Findings Overview

The following table provides a general clinical overview of the parameters evaluated during a Protein-C test, along with typical normal ranges and possible abnormal findings. Please note that reference ranges can vary slightly depending on the specific assay methodology and instrumentation used by the laboratory.

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Protein C Functional Activity (Clotting/Chromogenic)	70% to 140% (activity relative to normal pooled plasma)	Decreased (<70%): Indicates congenital (Type I or II) or acquired deficiency (liver disease, Vitamin K deficiency, Warfarin therapy, DIC, acute thrombosis). Elevated (>140%): Generally of limited clinical significance, occasionally seen in acute phase responses or metabolic syndromes.
Protein C Antigen Level (ELISA/Immunological)	70% to 140% (antigen concentration)	Decreased (<70%): Confirms Type I (quantitative) congenital deficiency or acquired deficiency. Normal (70-140%) with low activity: Diagnostic of Type II (qualitative) congenital deficiency.
Coagulation Cascade Regulation	Controlled thrombin generation; normal inactivation of Factors Va and VIIIa	Unregulated thrombin generation; persistent activity of Factors Va and VIIIa, leading to a hypercoagulable state and high risk of venous thrombosis.
Vitamin K-Dependent Synthesis	Fully carboxylated, functional Protein C molecules	Under-carboxylated, non-functional Protein C molecules (PIVKA-PC) due to Vitamin K deficiency or Warfarin therapy.
Neonatal Coagulation Status	Age-adjusted normal levels (typically lower in healthy neonates, 30-40%, gradually reaching adult levels)	Extremely low or undetectable (<5%): Diagnostic of homozygous or compound heterozygous congenital deficiency, presenting as neonatal purpura fulminans.
Systemic Coagulation Balance (DIC Screen)	Stable, non-consumed levels of regulatory proteins	Severely depleted Protein C levels due to systemic consumption in active Disseminated Intravascular Coagulation (DIC) or severe sepsis.
Hepatic Synthetic Function	Normal synthesis of coagulation inhibitors	Significantly reduced Protein C levels reflecting impaired synthetic capacity of the liver in cirrhosis or acute liver failure.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Protein-C?

• Experienced Healthcare Professionals: Dr. Essa Lab employs a highly qualified team of consultant pathologists, hematologists, and experienced laboratory technologists who specialize in complex coagulation disorders.
• Patient-Focused Care: The laboratory is dedicated to providing compassionate, patient-centric care, ensuring a comfortable and stress-free experience during sample collection.
• Quality Diagnostic Services: Operating under strict international quality control standards, Dr. Essa Lab ensures high precision, reproducibility, and clinical accuracy for all specialized assays.
• Professional Reporting: Reports are detailed, clearly structured, and include comprehensive reference ranges, reviewed and signed off by certified medical specialists.
• Modern Diagnostic Approach: Utilizing state-of-the-art, fully automated coagulation analyzers, the lab minimizes human error and ensures rapid processing of delicate blood samples.
• Comfortable Environment: All collection centers are designed to maintain a clean, hygienic, and welcoming environment, adhering to strict infection control protocols.
• Convenient Location: With an extensive network of branches across Karachi and other cities, patients can easily find a Dr. Essa Lab collection center near their home or workplace.
• Commitment to Accurate Diagnosis: Established in 1987, Dr. Essa Lab has built decades of trust in Pakistan’s healthcare sector, continually investing in advanced diagnostic technologies to support accurate clinical decision-making.